CAIX-targeted PET scan for kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial uses a special PET scan that targets a protein (CAIX) often found in kidney cancer cells. It helps doctors see the cancer more clearly, which may guide better treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You have suspected or confirmed kidney cancer (clear cell, papillary, or chromophobe type).
- You have had an enhanced CT scan in the last 2 weeks.
- Your blood test results show your liver and kidney function are within safe limits.
- You are willing to have a biopsy if you haven't already.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special imaging scan (68Ga-C1 PET/CT) to see kidney cancer more clearly. It helps doctors find and understand clear cell renal cell carcinoma, a common type of kidney cancer.
This early-stage trial tests a new type of imaging scan (called PET) that uses a special tracer to help doctors see tumors better. The scan targets a protein called CAIX that appears on many cancer cells, which may help with accurate diagnosis and staging.
This study tests a new kind of PET scan that might better detect kidney cancer. It involves an injection of a special imaging agent and a scan to see if the cancer shows up clearly.
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
This early-phase study tests a lab-made immune treatment (CAIX-targeted CAR-T cells) for advanced kidney cancer that has not gone away with standard targeted therapy or immunotherapy. If eligible, the goal is to see if the treatment can safely shrink the cancer and improve outcomes.
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.